Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National ...

Monument Therapeutics partners with FNIH to advance MT1988, a promising treatment for cognitive impairment in schizophrenia, ...

UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in ...

Dr. Kiri Granger, Chief Scientific Officer of Monument Therapeutics, commented: "This trial marks an exciting milestone for Monument to evaluate MT1988 in a patient population with our proprietary ...

This Investigational New Drug (IND)-opening clinical trial for MT1988 is the first patient trial from Monument's precision medicine pipeline.

Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...

(Alliance News) - Cambridge Cognition Holdings PLC on Tuesday said Monument Therapeutics, in which it holds a 20% stake, has partnered up on the development of a novel treatment for cognitive ...

CAMBRIDGE, UK - Monument Therapeutics has partnered with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment for cognitive impairment associated with ...